Literature DB >> 12402510

Effects of nitric oxide synthase inhibitors and melatonin on the hyperglycemic response to streptozotocin in rats.

V S N Rao1, F A Santos, R M Silva, M G Teixiera.   

Abstract

Recent studies evidence that peroxynitrite is spontaneously formed when nitric oxide (NO) and superoxide coexist and suggest that it is likely to be involved in the destruction of the pancreatic beta cells. We examined whether drugs that inhibit nitric oxide synthase (NOS) or scavenge peroxynitrite could abrogate STZ-induced hyperglycemia in rats. Blood glucose levels were measured before (0 h) and 24, 48, and 72 h following intraperitoneal administration of 60 mg/kg streptozotocin (STZ). The levels of blood sugar in STZ-treated control animals were significantly elevated at all time points of observation with a peak increase at 48 h. The hyperglycemic response of STZ was found to be significantly reduced in animals pretreated with aminoguanidine (50 mg/kg i.p.), an inducible isoform-selective NOS (iNOS) inhibitor with antioxidant property, and by melatonin (6 mg/kg i.p.), an antioxidant that also prevents peroxynitrite formation but not by Nw-nitro-L-arginine methyl ester (L-NAME, 10 mg/kg i.p.), and 7-nitroindazole (7-NI, 50 mg/kg i.p.), the constitutive inhibitors of endothelial and neuronal NOS, respectively. These findings indicate the possible participation of iNOS-derived NO as well as oxygen free radicals in STZ-induced pancreatic beta cell destruction and compounds that act as scavengers of peroxynitrite may offer protection against such a damage.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12402510     DOI: 10.1016/s1537-1891(02)00212-4

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  11 in total

Review 1.  Melatonin and nitric oxide.

Authors:  S Aydogan; M Betul Yerer; A Goktas
Journal:  J Endocrinol Invest       Date:  2006-03       Impact factor: 4.256

2.  Role of melatonin on diabetes-related metabolic disorders.

Authors:  Javier Espino; José A Pariente; Ana B Rodríguez
Journal:  World J Diabetes       Date:  2011-06-15

Review 3.  Metabolic effects of melatonin on oxidative stress and diabetes mellitus.

Authors:  Shigeru Nishida
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

Review 4.  Oxidative stress and beta-cell dysfunction.

Authors:  Gisela Drews; Peter Krippeit-Drews; Martina Düfer
Journal:  Pflugers Arch       Date:  2010-07-23       Impact factor: 3.657

5.  Role of gastric oxidative stress and nitric oxide in formation of hemorrhagic erosion in rats with ischemic brain.

Authors:  Chen-Road Hung
Journal:  World J Gastroenterol       Date:  2006-01-28       Impact factor: 5.742

Review 6.  Melatonin: an established antioxidant worthy of use in clinical trials.

Authors:  Ahmet Korkmaz; Russel J Reiter; Turgut Topal; Lucien C Manchester; Sukru Oter; Dun-Xian Tan
Journal:  Mol Med       Date:  2008-11-04       Impact factor: 6.354

7.  The effects of the melatonin treatment on the oxidative stress and apoptosis in diabetic eye and brain.

Authors:  Tuğba Gürpınar; Nuran Ekerbiçer; Nazan Uysal; Turgay Barut; Figen Tarakçı; M Ibrahim Tuglu
Journal:  ScientificWorldJournal       Date:  2012-05-01

8.  Effect of Melatonin Intake on Oxidative Stress Biomarkers in Male Reproductive Organs of Rats under Experimental Diabetes.

Authors:  Marina G Gobbo; Carolina F Pereira Costa; Danilo G Humberto Silva; Eduardo A de Almeida; Rejane M Góes
Journal:  Oxid Med Cell Longev       Date:  2015-05-06       Impact factor: 6.543

9.  Exercise Training and Grape Seed Extract Co-Administration Improves Lipid Profile, Weight Loss, Bradycardia, and Hypotension of STZ-Induced Diabetic Rats.

Authors:  Mohammad Badavi; Hassan Ali Abedi; Mahin Dianat; Ali Reza Sarkaki
Journal:  Int Cardiovasc Res J       Date:  2013-12-01

10.  Superoxide dismutase analog (Tempol: 4-hydroxy-2, 2, 6, 6-tetramethylpiperidine 1-oxyl) treatment restores erectile function in diabetes-induced impotence.

Authors:  T Kawakami; S Urakami; H Hirata; Y Tanaka; K Nakajima; H Enokida; H Shiina; T Ogishima; T Tokizane; K Kawamoto; K Miura; N Ishii; R Dahiya
Journal:  Int J Impot Res       Date:  2009-06-25       Impact factor: 2.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.